Marfan syndrome (MFS) is an inherited connective tissue disorder caused by heterozygous mutations in the FBN1 gene. Clinical manifestations of MFS include aortic dilatation and dissection, as well as cardiac valvular, ocular, skeletal and neurological manifestations. Prevalence varies from 6 to 20 per 100,000 individuals. Revised Ghent Nosology (2010) is used to establish a clinically based suspected diagnosis to be confirmed by molecular testing. This Utility Gene Test was prepared on the basis of an analysis of the literature and existing diagnostic protocols. Molecular testing is useful for diagnosis confirmation, as well as differential diagnosis, appropriate genetic counselling and access to clinical trials.
Genetic testing for Marfan syndrome
organ to be diagnosed with MFS (7, 8) . The following multiple diagnostic modalities and methods are regularly used to diagnose MFS: clinical examination and history, heart ultrasound, eye examination with slit lamp for lens dislocation, advanced imaging studies of the vascular tree, and genetic testing for mutations in FBN1.
The differential diagnosis should consider Loeys-Dietz syndromes, congenital contractural arachnodactyly/Beals syndrome, non-syndromic familial thoracic aortic disease, Ehlers-Danlos syndromes, homocystinuria caused by cystathionine β-synthase deficiency, Stickler syndrome and fragile X syndrome.
MFS has autosomal dominant inheritance. Approximately 75% of individuals with MFS have an affected parent and approximately 25% have a de novo pathogenic variant in FBN1 (9) .
Pathogenic variants may include missense, nonsense, small insertions, small deletions, small indels and gross deletions (10) .
Aims of the test
• To determine the gene defect responsible for the disease;
• To confirm clinical diagnosis;
• To assess the recurrence risk and perform genetic counselling for at-risk/affected individuals.
Test characteristics

Specialist centers/ Published Guidelines
The test is listed in the Orphanet database and is offered by 44 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 28 accredited medical genetic laboratories in the US. Guidelines for clinical use of the test are described in Genetics Home Reference (ghr.nlm.nih.gov) and Gene Reviews (9) .
Test strategy
In patients meeting the revised Ghent criteria and after exclusion of partially overlapping disorders, we advise Sanger sequencing for the detection of nucleotide variations in coding exons and flanking introns in the FBN1 gene. Sanger sequencing is also used for family segregation studies.
Multiplex Ligation Probe Amplification (MLPA) is used to detect duplications and deletions in FBN1.
In incomplete phenotypes that only meet some of the revised Ghent criteria or overlapping phenotypes with mixed features of MFS and other Marfan-like conditions, a wider approach with next generation resources (e.g. customized gene panels or exome analysis) may be considered in highly specialized settings.
To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml peripheral blood in a sterile tube with 0.5 ml K 3 EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated.
Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results
Positive
Identification of a pathogenic variant in the FBN1 gene confirms the clinical diagnosis and is an indication for family studies. A pathogenic variant is known to be causative for a given genetic disorder based on previous reports, or predicted to be causative based on loss of protein function or expected significant damage to proteins or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance (VUS): a new variation without any evident pathogenic significance or a known variation with insufficient evidence (or with conflicting evidence) to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives to assess variant segregation and clarify its contribution. In some cases, it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test.
Unexpected
Unexpected results may emerge from the test, for example information regarding consanguinity, absence of family correlation or other genetically based diseases.
Risk for progeny
In autosomal dominant transmission, the probability that an affected carrier transmit the variant to his/her children is 50% in any pregnancy, irrespective of the sex of the child conceived.
Limits of the test
The test is limited by current scientific knowledge regarding the gene and disease. Clinical specificity: data not available.
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for MFS; b) the sensitivity of the test is greater than or equal to that of tests described in the literature.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis Yes
Differential diagnosis Yes
Couple risk assessment Yes
Availability of clinical trials can be checked on-line at https://clinicaltrials.gov/
